CD8A and neoplasm: Therefore, some anti-PD-L1 mAbs may act as both tumor antigen-targeting antibodies and anti-PD-L1 inhibitors, which leads to the activation of NK cell and CD8+ T cell and improvement in therapeutic efficacy.